This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Switching antidepressant (SSRIs to moclobemide) in adults

Authoring team

SSRIs to moclobemide

Taper, washout and switch

  • for any SSRI, you should gradually reduce the dose and stop
    • will then need to wait for a period, dependent on the antidepressant being switched from (see below), before starting moclobemide.

Cross-tapering is not recommended due to the high risk of serotonin syndrome.

From all except fluoxetine and sertraline

  • after stopping the SSRI, wait 7 days before starting moclobemide.

From fluoxetine

  • after stopping fluoxetine, wait 5 to 6 weeks before starting moclobemide
    • clinicians should decide the duration of the washout period on a case-by-case basis
  • fluoxetine may still cause medicine interactions 5 or 6 weeks after stopping, as fluoxetine and its active metabolite have a long half-life

From sertraline

  • after stopping sertraline, wait 7 to 13 days before starting moclobemide
    • manufacturer advises a 7 day washout period but 13 days may be considered to account for the long half-life of sertraline's active metabolite
    • clinicians should decide the duration of the washout period on a case-by-case basis

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.